A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Description

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

Conditions

Healthy Volunteers, Pulmonary Arterial Hypertension

Talk to us

Study Overview

On this page

Study Details

Study overview

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate the Efficacy and Safety of LTP001 for the Treatment of Participants With Pulmonary Arterial Hypertension (Part B)

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Condition
Healthy Volunteers, Pulmonary Arterial Hypertension
Intervention / Treatment

-

Contacts and Locations

Austin

PPD Development LP, Austin, Texas, United States, 78744

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Healthy males and non-child-bearing potential females
  • * Clinically significant ECG or cardiac abnormalities, any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the participant in the study Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Novartis Pharmaceuticals,

Study Record Dates

2026-09-03